PLXProtalix BioTherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Protalix BioTherapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLXEsta | $217M#8 | 11.7x#2 | 3.0x#8 | 4.1x#1 | -1.2%#4 | -325.2%#14 | -10.4%#1 | -9.2%#3 | -12.3%#1 | 3#1 | 46.2%#4 | — |
| SABS | $319M#1 | 14.6x#3 | 1.5x#4 | — | -100.0%#9 | 138.9%#2 | — | 6.2%#2 | — | — | 35.5%#6 | — |
| PALI | $297M#3 | 2.6x#1 | 2.4x#7 | — | — | -16.2%#6 | — | -13.8%#4 | — | — | 192.0%#1 | — |
| FATE | $297M#2 | — | 1.9x#5 | 44.7x#8 | -51.2%#6 | 26.8%#4 | -2222.4%#10 | -88.8%#10 | -102.3%#2 | — | 160.1%#2 | — |
| LCTX | $264M#4 | — | 4.3x#12 | 18.2x#6 | 53.2%#3 | -241.4%#12 | -251.6%#4 | -104.3%#11 | — | — | -24.5%#10 | — |
| TARA | $219M#7 | — | 1.4x#3 | 74.2x#10 | — | -28.7%#9 | -2189.6%#9 | -35.6%#6 | — | — | 21.3%#7 | — |
| IVVD | $221M#6 | — | 1.2x#2 | 4.1x#2 | 110.5%#1 | 69.1%#3 | -104.0%#2 | -29.0%#5 | — | — | -35.2%#12 | — |
| AVXL | $226M#5 | — | 2.0x#6 | — | — | -7.8%#5 | — | -41.2%#8 | — | — | -72.3%#14 | — |
| ALEC | $208M#9 | — | — | 9.9x#5 | -79.1%#8 | -20.2%#8 | -741.3%#7 | — | — | — | -36.7%#13 | — |
| SRZN | $200M#10 | — | — | 57.6x#9 | -67.4%#7 | -280.8%#13 | -1210.6%#8 | — | — | — | 43.8%#5 | — |
| ACOG | $191M#12 | — | 3.6x#11 | 18.7x#7 | — | -39.8%#10 | -221.7%#3 | -39.0%#7 | — | — | 5.0%#8 | — |
| VYGR | $186M#13 | — | 1.2x#1 | 4.6x#4 | -49.5%#5 | -84.2%#11 | -326.6%#5 | -77.6%#9 | — | — | -29.2%#11 | — |
| CHRS | $193M#11 | — | 3.2x#9 | 4.6x#3 | 59.8%#2 | 489.4%#1 | -429.5%#6 | 276.2%#1 | -351.2%#3 | — | -7.7%#9 | — |
| ABOS | $186M#14 | — | 3.3x#10 | — | — | -18.6%#7 | — | -211.9%#12 | -421.4%#4 | — | 104.4%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice